Search research articles
Contact Us
Filters
Showing results (71-80 of 85) with videos related to
Page
of 9
Sort By:
JAMA Oncology
|
December 11, 2025
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial
Irene M Kang, Jamie K Forschmiedt, Michelle M Loch, et al.
Journal of the National Cancer Institute
|
March 6, 2015
Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32
Pamela J Goodwin, Wendy R Parulekar, Karen A Gelmon, et al.
Journal of the National Cancer Institute
|
December 10, 2024
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial
Yara Abdou, William E Barlow, Julie R Gralow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2023
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
Marion T van Mackelenbergh, Sibylle Loibl, Michael Untch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 28, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy
Pierre Squifflet, Everardo D Saad, Sibylle Loibl, et al.
NPJ Breast Cancer
|
June 9, 2021
Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial
Pamela J Goodwin, Ryan J O Dowling, Marguerite Ennis, et al.
JAMA
|
May 24, 2022
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial
Pamela J Goodwin, Bingshu E Chen, Karen A Gelmon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 21, 2020
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Stephen R D Johnston, Nadia Harbeck, Roberto Hegg, et al.
The New England Journal of Medicine
|
December 6, 2018
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Gunter von Minckwitz, Chiun-Sheng Huang, Max S Mano, et al.
Journal of the National Cancer Institute
|
November 23, 2013
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31
Katherine L Pogue-Geile, Chungyeul Kim, Jong-Hyeon Jeong, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 85) with videos related to
Sort By:
Page
of 9
JAMA Oncology
|
December 11, 2025
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial
Irene M Kang, Jamie K Forschmiedt, Michelle M Loch, et al.
Journal of the National Cancer Institute
|
March 6, 2015
Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32
Pamela J Goodwin, Wendy R Parulekar, Karen A Gelmon, et al.
Journal of the National Cancer Institute
|
December 10, 2024
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial
Yara Abdou, William E Barlow, Julie R Gralow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2023
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
Marion T van Mackelenbergh, Sibylle Loibl, Michael Untch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 28, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy
Pierre Squifflet, Everardo D Saad, Sibylle Loibl, et al.
NPJ Breast Cancer
|
June 9, 2021
Effect of metformin versus placebo on metabolic factors in the MA.32 randomized breast cancer trial
Pamela J Goodwin, Ryan J O Dowling, Marguerite Ennis, et al.
JAMA
|
May 24, 2022
Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial
Pamela J Goodwin, Bingshu E Chen, Karen A Gelmon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 21, 2020
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Stephen R D Johnston, Nadia Harbeck, Roberto Hegg, et al.
The New England Journal of Medicine
|
December 6, 2018
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Gunter von Minckwitz, Chiun-Sheng Huang, Max S Mano, et al.
Journal of the National Cancer Institute
|
November 23, 2013
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31
Katherine L Pogue-Geile, Chungyeul Kim, Jong-Hyeon Jeong, et al.
Page
of 9